Gene Therapy Shows Promise for Muscular Dystrophy
A new systematic review finds that delandistrogene moxeparvovec improves mobility and protein levels in young patients.
Updated on Oct. 26, 2026 in Children’s Health
Live Poll
Do you trust emerging gene therapies to effectively treat rare diseases in pediatric patients?
A systematic review of clinical studies indicates that the gene therapy delandistrogene moxeparvovec improves functional outcomes in pediatric patients with Duchenne muscular dystrophy. Researchers observed gains in mobility and muscle dystrophin content compared to baseline measures after 12 months.
Why it matters
Duchenne muscular dystrophy remains a challenging condition, as current therapeutic options typically offer only short-term benefits. This study provides evidence that this specific gene therapy may offer a more sustained impact on physical function for children living with the disease.
The analysis revealed a mean difference of 2.55 in North Star Ambulatory Assessment scores and a 28.39 increase in muscle dystrophin content. These metrics represent results gathered at a 12-month follow-up period.
The details
Researchers performed a systematic review of four existing studies sourced from databases including Cochrane, PubMed, and Embase to evaluate therapy outcomes. The assessment focused on functional markers such as time-to-rise scores and performance on 10-meter walk/run tests.
Timeline
12-month follow-up data collection for the study participants.
The Big Picture
This systematic review aligns with the broader investigation into gene-based interventions for Duchenne muscular dystrophy. It contributes to the evolving scientific understanding of how genetic therapies may alter the progressive decline typically associated with this diagnosis.
The findings suggest a potential improvement in mobility for pediatric patients treated with this therapy. Families and providers should consult specialists to understand how these clinical outcomes may translate into personalized treatment plans.
The takeaway
This study underscores the potential for genetic interventions to improve physical function in children with Duchenne muscular dystrophy. Patients and their families should continue to prioritize long-term monitoring as new data on these therapies emerges.
Further reading
For more information on pediatric treatments, visit our Children’s Health section.
Source note: This article includes information reported by Derm Immuno Today.
Live Poll
Do you trust emerging gene therapies to effectively treat rare diseases in pediatric patients?
